Reliability of the Heparin Management Test for Monitoring High Levels of Unfractionated Heparin: In Vitro Findings in Volunteers versus In Vivo Findings during Cardiopulmonary Bypass
暂无分享,去创建一个
A. Koster | G. J. Crystal | R. Hansen | F. Mertzlufft | H. Kuppe | Fritz Mertzlufft | Anne Risch | Herrmann Kuppe | Bernhard Kübel | George J. Crystal
[1] M. Abdelnoor,et al. Assessment of heparin anticoagulation: comparison of two commercially available methods. , 1999, The Annals of thoracic surgery.
[2] Daniel W Byrne,et al. Heparin management test versus activated coagulation time during cardiovascular surgery: correlation with anti-Xa activity. , 1999, Journal of cardiothoracic and vascular anesthesia.
[3] J. Ramsay,et al. Protamine Reversal of Heparin Affects Platelet Aggregation and Activated Clotting Time After Cardiopulmonary Bypass , 1998, Anesthesia and analgesia.
[4] W. Weightman,et al. Evaluation of the TAS coagulation analyzer for monitoring heparin effect in cardiac surgical patients. , 1998, Journal of cardiothoracic and vascular anesthesia.
[5] R. Hetzer,et al. Emergent cardiopulmonary bypass in five patients with heparin-induced thrombocytopenia type II employing recombinant hirudin. , 1998, Anesthesiology.
[6] P. Lyden,et al. The diagnostic accuracy of bedside and laboratory coagulation: procedures used to monitor the anticoagulation status of patients treated with heparin. , 1998, American journal of clinical pathology.
[7] F. Mertzlufft,et al. IMPACT OF APROTININ ON ACT AND HMT DURING CABG , 1998 .
[8] D. Reich,et al. Heparin and protamine titration do not improve haemostasis in cardiac surgical patients , 1998, Canadian journal of anaesthesia = Journal canadien d'anesthesie.
[9] Y. Okita,et al. Coagulation and fibrinolysis system in aortic surgery under deep hypothermic circulatory arrest with aprotinin: the importance of adequate heparinization. , 1997, Circulation.
[10] K. Hayashi,et al. [A clinical evaluation of the Hepcon/HMS: a new device of monitoring hemostasis management during cardiopulmonary bypass]. , 1997, Kyobu geka. The Japanese journal of thoracic surgery.
[11] F. Mertzlufft,et al. [The "TAS-Analyzer"]. , 1997, Der Anaesthesist.
[12] E. Spitznagel,et al. More Effective Suppression of Hemostatic System Activation in Patients Undergoing Cardiac Surgery by Heparin Dosing Based on Heparin Blood Concentrations rather than ACT , 1996, Thrombosis and Haemostasis.
[13] S. Bélisle,et al. CARDIOPULMONARY BYPASS , MYOCARDIAL MANAGEMENT , AND SUPPORT TECHNIQUES MEASUREMENT OF HEPARIN CONCENTRATION IN WHOLE BLOOD WITH THE HEPCON / HMS DEVICE DOES NOT AGREE WITH LABORATORY DETERMINATION OF PLASMA HEPARIN CONCENTRATION USING A CHROMOGENIC SUBSTRATE FOR ACTIVATED FACTOR X , 2004 .
[14] E. Spitznagel,et al. Response of kaolin ACT to heparin: evaluation with an automated assay and higher heparin doses. , 1996, The Annals of thoracic surgery.
[15] K. T. Benson. Blood: Hemostasis, Transfusion, and Alternatives in the Perioperative Period , 1995 .
[16] M. Wolzt,et al. Studies on the Neutralizing Effects of Protamine on Unfractionated and Low Molecular Weight Heparin (Fragmin®) at the Site of Activation of the Coagulation System in Man , 1995, Thrombosis and Haemostasis.
[17] R. Karp,et al. Monitoring of heparin-induced anticoagulation with kaolin-activated clotting time in cardiac surgical patients treated with aprotinin. , 1992, Anesthesiology.
[18] R. Baugh,et al. Heparinase in the activated clotting time assay: monitoring heparin-independent alterations in coagulation function. , 1992, Anesthesia and analgesia.
[19] K. M. Taylor,et al. EFFECT OF APROTININ ON NEED FOR BLOOD TRANSFUSION AFTER REPEAT OPEN-HEART SURGERY , 1987, The Lancet.
[20] Robert K. Stoelting,et al. Pharmacology and physiology in anesthetic practice , 1987 .
[21] F. Spencer,et al. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. , 1981, Annals of surgery.